DermaCare: Zapping Zits Directly

Richard G. Hamermesh; Lauren  Barley

Case | HBS Case Collection | September 2007 (Revised October 2010)

DermaCare: Zapping Zits Directly

by Richard G. Hamermesh and Lauren Barley

Abstract

DermaCare has developed an innovative new product for the treatment of acne that they hope to sell to consumers via direct-response television. The unconventional nature of the product and its distribution has led the company to seek angel financing. The Silicon Valley Band of Angels has agreed to finance the company and has submitted a proposed term sheet. Recently, however, a venture capital (VC) group has submitted a competing term sheet. The company must decide whether to accept financing from the Angels or the VC group.

Keywords: Decision Choices and Conditions; Venture Capital; Investment; Innovation and Invention; Product; California;

Format: Print

21 pages

Educators Purchase

Citation:

Hamermesh, Richard G., and Lauren Barley. "DermaCare: Zapping Zits Directly." Harvard Business School Case 808-064, September 2007. (Revised October 2010.)

The case is set in March 2019, and tells the story of the founding of the Dementia Discovery Fund (DDF). The idea for the fund began in 2015, when then-Prime Minister David Cameron spoke about the importance of making breakthroughs in dementia research, and pledged money from the UK government for research. This in turn led to the search for a venture capital (VC) firm that could lead manage a fund, and the selection of SV Health to do that, including having Kate Bingham as a managing partner. The case describes the social and scientific needs for more dementia research, as well as the fundraising and initial team building of the fund. After the fund grows beyond the expected size, the case describes the hiring of a CEO, and asks what the next investment for the fund should be: a start-up that might soon be able to launch clinical trials, or an early-stage company with promising new research?

It is early 2018, and Emily Park, managing director of impact for the Abreu Family Office, is meeting the next day with Tomás and Maria Abreu to discuss the various ways in which the Abreus can allocate a planned $100 million to make a meaningful difference in cancer patients’ lives. Park has spent the past few months working on this project and has uncovered a multitude of options, from supporting high-performing disease-focused organizations through venture philanthropy; to investing in a fund or directly into ventures and possibly earning a good return on investment in the process; to helping address system-wide issues such as the better organization and funding of clinical trials. As she prepares to present her findings to the Abreus, she wonders which one(s) will spark their interest as the way to have the most meaningful impact, and what implications their ultimate decision will have on the Family Office in terms of its capital outlays, structure, staffing, and many other categories.

Faculty & Research

DermaCare: Zapping Zits Directly

Abstract

Citation:

About the Author

More from the Author